Back to top

MTN-037 is a Phase 1, open label, sequential dose/volume escalation study designed to evaluate the safety and pharmacokinetics of PC-1005 (MIV-150/Zinc Acetate/Carrageenan gel) when administered rectally in men and women (cis or transgender.) 

Protocol Chair(s)
Hendrix, Craig (Protocol Chair)
Protocol Title
A Phase 1 Safety and Pharmacokinetic Study of PC-1005 (MIV-150/Zinc Acetate/Carrageenan Gel) Administered Rectally to HIV-1 Seronegative Adults
DAIDS Protocol ID
35122
Status
Pending
Formulation
Gel
Drug
PC‐1005 (MIV‐150/Zinc Acetate/Carrageenan Gel)  
Study Focus/Product Administration
Rectal
Study Type
Behavioral
Pharmacokinetics
Safety
Study Phase
Phase I  
Countries
United States
Population
Men (cisgender men, non‐transgender men)   
Transgender women
Women (cisgender women, non‐transgender women)
Funder(s)
DAIDS
Sponsor(s)
Population Council
Other Study Info

Phase 1, open label, sequential dose/volume escalation trial